[Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement]

W Chen1, Q X Gong1, X Li1

  • 1Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Insights

Large B-cell lymphoma (LBCL) with IRF4 rearrangement presents distinct clinicopathological features. Further studies are needed to determine the relationship between clinical stage and prognosis in these cases.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Large B-cell lymphoma (LBCL) is a heterogeneous group of lymphoid malignancies.
  • The role of IRF4 rearrangement in LBCL pathogenesis and its clinicopathological significance require further elucidation.

Purpose of the Study:

  • To investigate the clinicopathological characteristics of LBCL associated with IRF4 gene rearrangement.
  • To analyze the morphological, immunophenotypic, and genetic features of these specific LBCL cases.

Main Methods:

  • Retrospective analysis of seven LBCL cases with IRF4 rearrangement.
  • Evaluation using hematoxylin and eosin staining, immunohistochemistry, and fluorescence in situ hybridization.
  • Review of relevant scientific literature.

Main Results:

  • Cases presented with diverse locations (tonsils, lymph nodes, adenoid) and varied histological patterns (follicular, diffuse).
  • Tumor cells showed medium to large size with centroblastic or blastoid morphology; high Ki-67 index (>80%) was observed in all cases.
  • IRF4 gene rearrangement was consistently detected, with bcl-6 rearrangement in two cases; immunophenotype included CD20, PAX-5, bcl-6, and MUM1 positivity.

Conclusions:

  • LBCL with IRF4 rearrangement represents a distinct clinicopathological entity.
  • These findings suggest a broader spectrum of morphological and behavioral patterns in IRF4-rearranged LBCL.
  • Prospective studies with larger cohorts are necessary to establish the prognostic implications of clinical stage.

Related Concept Videos